Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, has launched ZetaOmics, the computational biology module of its multi-agentic AI co-scientist platform, withZeta.ai. The platform introduces an autonomous 'Computational Biologist' agent designed to perform end-to-end bioinformatics and multi-omic analysis across cancer types. Initially available through an early-access program for select academic, industry and company collaborators, the platform is designed to automate complex research workflows while embedding domain-specific intelligence intended to improve analytical rigor and reproducibility.
According to the company, ZetaOmics combines 14 specialized tools that can autonomously design, execute and validate biological analyses, detect potential flaws in experimental design and generate publication-quality results with a complete audit trail. Lantern said the platform expands withZeta.ai’s commercial opportunity beyond rare cancers by targeting academic medical centers, biotechnology and pharmaceutical companies, cancer centers and contract research organizations through subscription-based offerings and strategic collaborations.
This launch underscores Lantern's commitment to leveraging artificial intelligence to transform drug development. The ZetaOmics platform is part of the company's broader strategy to generate new revenue streams through subscription-based research tools for the global biomedical community. Lantern's clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
For more details on the launch, visit the full press release at https://ibn.fm/9sIIl. Additional information about Lantern Pharma and its latest developments can be found in the company’s newsroom at https://ibn.fm/LTRN.
